Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma

다국어 초록 (Multilingual Abstract)

Background: Medullary thyroid carcinoma (MTC) has a poorer prognosis than differentiated thyroid cancers; however, comprehensive data on the long-term outcomes of MTC remain scarce. This study investigated the extended clinical outcomes of MTC and aimed to identify prognostic factors.
Methods: Patients diagnosed with MTC between 1980 and 2020 were retrospectively reviewed. Their clinical characteristics, longterm clinical outcomes, and prognostic factors for recurrence and mortality were analyzed.
Results: The study included 226 patients (144 women, 82 men). The disease-specific survival (DSS) rates for all MTC patients at 5-, 10-, 20-, and 30-year intervals were 92.7%, 89.4%, 74.3%, and 68.1%, respectively. The recurrence-free survival (RFS) rates were 71.1%, 56.1%, 40.2%, and 32.1% at these intervals. DSS was comparable between the groups from 1980–2009 and 2010–2020 (P=0.995); however, the 1980–2009 group had significantly lower RFS rates (P=0.031). The 2010–2020 group exhibited greater extents of surgical and lymph node dissection (P=0.003) and smaller tumors (P=0.003). Multivariate analysis identified extrathyroidal extension as the strongest prognostic factor for both RFS and DSS. Age >55 years and tumor size of ≥2 cm were also significant prognostic factors for DSS, while hereditary disease and lymph node metastasis were significant for RFS. Survival analysis after propensity-score matching of rearranged during transfection (RET)-negative and non-screened RET-positive groups showed comparable DSS but longer RFS in the RET-negative group.
Conclusion: Extrathyroidal extension was identified as the strongest prognostic factor for RFS and DSS. Older age and larger tumor size were associated with decreased DSS, while RET mutation and lymph node metastasis significantly impacted RFS.

참고문헌 (Reference)

• 1 Kaliszewski K, "Update on the diagnosis and management of medullary thyroid cancer : what has changed in recent years?" 14 : 3643-, 2022
• 2 Opsahl EM, "Trends in diagnostics, surgical treatment, and prognostic factors for outcomes in medullary thyroid carcinoma in Norway : a nationwide population-based study" 8 : 31-40, 2019
• 3 Filetti S, "Thyroid cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" 30 : 1856-1883, 2019
• 4 Machens A, "Therapeutic effectiveness of screening for multiple endocrine neoplasia type 2A" 100 : 2539-2545, 2015
• 5 Ahn JH, "The association between vitamin D supplementation and the long-term prognosis of differentiated thyroid cancer patients : a retrospective observational cohort study with propensity score matching" 14 : 1163671-, 2023
• 6 문신제 ; 박영주 ; 이은경 ; 최훈성 ; Sue K. Park, "Survival comparison of incidentally found versus clinically detected thyroid cancers : an analysis of a nationwide cohort study" 38 : 81-92, 2023
• 7 Tao Z, "Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000-2020 : a populationbased retrospective cohort study" 31 : e230319-, 2024
• 8 Choi H, "Secular trends in the prognostic factors for papillary thyroid cancer" 171 : 667-675, 2014
• 9 Wells SA Jr, "Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma" 25 : 567-610, 2015
• 10 Prabhu M, "RET gene mutation analysis and long-term clinical outcomes of medullary thyroid cancer patients" 41 : 1136-1142, 2020
• 11 Modigliani E, "Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma : results in 899 patients. The GETC Study Group. Groupe d’étude des tumeurs à calcitonine" 48 : 265-273, 1998
• 12 Jung KY, "Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer : a large-scale retrospective analysis over 30 years" 84 : 587-597, 2016
• 13 Moley JF, "Patterns of nodal metastases in palpable medullary thyroid carcinoma : recommendations for extent of node dissection" 229 : 880-888, 1999
• 14 Alevizaki M, "Medullary thyroid carcinoma : the influence of policy changing in clinical characteristics and disease progression" 167 : 799-808, 2012
• 15 Kebebew E, "Medullary thyroid carcinoma : clinical characteristics, treatment, prognostic factors, and a comparison of staging systems" 88 : 1139-1148, 2000
• 16 Cho Rok Lee ; Sohee Lee ; Haiyoung Son ; Eunjeong Ban ; Sang-Wook Kang ; Jandee Lee ; Jong Ju Jeong ; Kee-Hyun Nam ; Woong Youn Chung ; Cheong Soo Park, "Medullary thyroid carcinoma : a 30-year experience at one institution in Korea" 91 : 278-287, 2016
• 17 Pacini F, "Medullary thyroid carcinoma" 22 : 475-485, 2010
• 18 Hyer SL, "Medullary thyroid cancer : multivariate analysis of prognostic factors influencing survival" 26 : 686-690, 2000
• 19 American Thyroid Association Guidelines Task Force, "Medullary thyroid cancer : management guidelines of the American Thyroid Association" 19 : 565-612, 2009
• 20 Brierley J, "Medullary thyroid cancer : analyses of survival and prognostic factors and the role of radiation therapy in local control" 6 : 305-310, 1996
• 21 Dralle H, "Lymph node dissection and medullary thyroid carcinoma" 89 : 1073-1075, 2002
• 22 Elisei R, "Looking for RET alterations in thyroid cancer : clinical relevance, methodology and timing" 81 : 206-215, 2023
• 23 Raue F, "Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma : 40 years of experience at one center" 104 : 4264-4272, 2019
• 24 Pellegriti G, "Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging" 88 : 1537-1542, 2003
• 25 Torresan F, "Long-term outcome after surgery for medullary thyroid carcinoma : a single-center experience" 42 : 367-375, 2018
• 26 Cupisti K, "Long-term clinical and biochemical follow-up in medullary thyroid carcinoma : a single institution’s experience over 20 years" 246 : 815-821, 2007
• 27 Elisei R, "Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer : experience in 10, 864 patients with nodular thyroid disorders" 89 : 163-168, 2004
• 28 Jung KY, "Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea" 164 : 312-318, 2018
• 29 Vierhapper H, "Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders" 15 : 1267-1272, 2005
• 30 Asimakopoulos P, "Differentiated and medullary thyroid cancer : surgical management of cervical lymph nodes" 29 : 283-289, 2017
• 31 de Groot JW, "Determinants of life expectancy in medullary thyroid cancer : age does not matter" 65 : 729-736, 2006
• 32 김미진 ; 김보현, "Current guidelines for management of medullary thyroid carcinoma" 36 : 514-524, 2021
• 33 Franc S, "Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma" 55 : 403-409, 2001
• 34 Cho BY, "Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades" 23 : 797-804, 2013
• 35 Karga H, "Changes in risk factors and tumor node metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin" 60 : 604-608, 2011
• 36 Xu B, "Association of the genomic profile of medullary thyroid carcinoma with tumor characteristics and clinical outcomes in an international multicenter study" 34 : 167-176, 2024
• 37 Sahli ZT, "Association between age and disease specific mortality in medullary thyroid cancer" 221 : 478-484, 2021
• 38 Elisei R, "Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? : study on 4187 patients from a single Italian institution to answer this question" 95 : 1516-1527, 2010
• 39 Schlumberger M, "2012 European Thyroid Association guidelines for metastatic medullary thyroid cancer" 1 : 5-14, 2012